Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
about
Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patientsA randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.Fosamprenavir calcium plus ritonavir for HIV infection.Web resources for HIV type 1 genotypic-resistance test interpretation.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapyEfficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice.Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.Predictors of virological response to atazanavir in protease inhibitor-experienced patients.Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients
P2860
Q30564087-3AD24E4A-F6BC-49C2-A1FD-DB2AF23EACDBQ33345228-A431D545-9286-46C0-82E2-4C7987EF1349Q33559216-319BA64E-4ED6-4AFC-BE1D-81BAE38404ABQ33769950-BA73F903-14CD-4D2A-A4DF-8F1B596DCDF5Q34114808-01DCEEBB-37DD-488A-9B4E-6EFD50D958D4Q35120811-BD476E6A-9949-4EA3-ADBA-B4C363685C21Q35758975-CAC407A5-5091-42BB-B0A1-692C53A339B7Q35894312-7895254C-A665-43B1-9A88-56A0758C5858Q35917140-4B63AFC6-D35A-4567-B6EF-94C5A8FDB9B2Q36376533-D5F0DD14-42D9-4A23-AEF7-B633420DEE49Q36482890-3DAF8977-DE27-4050-8D49-DA7A164D9711Q36839698-15BE4B39-49F8-4907-B063-9BE4BAFC4069Q36899999-121993A6-5D7E-4D1D-8E3D-3B4DB92C1C35Q37189622-C5F1D5AF-6020-4AD0-916E-B3FD88E45EE6Q37204276-D39EBC6D-76B0-47CA-8354-63FE255A33E0Q37379360-B66C83A8-7178-40FE-A378-1D1D45F1313FQ37392816-10E0D1B7-B9BE-4541-8AA3-FD96F3DC31E3Q38954109-74CF5505-5D9A-4EB2-8321-CD857C299BEFQ40131713-A900100B-2A5B-4BBC-B664-E82773560FDAQ40424278-9AA3F1D7-5E51-4481-8633-C7E04634FA07Q43199280-71D6E562-FFF2-4BF6-A9D2-0D9DD75B9CECQ43469365-9C35A1AB-B51B-4D2D-875A-0A2B50B97880Q44965782-33C2ED54-B658-45A3-9844-2177F156ABD4Q45096975-C2854139-1FCA-4528-BE6E-956F5250EB8FQ46571246-40D1ADA9-95A1-4C21-A838-B528E7AE58C0Q53851252-701B3EB3-6C4C-45E0-978F-19A520E02CC3Q58204783-BDEDA7F1-8E7F-42C2-BF20-2BF6F51203DF
P2860
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@ast
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@en
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@nl
type
label
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@ast
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@en
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@nl
prefLabel
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@ast
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@en
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@nl
P2093
P2860
P50
P1476
Genotypic inhibitory quotient ...... inhibitor-experienced patients
@en
P2093
Anne Simon
Anne-Geneviève Marcelin
Claire Lamotte
Constance Delaugerre
Genophar Study Group
Hocine Ait Mohand
Manuela Bonmarchand
Marc Wirden
Nadine Ktorza
Philippe Bossi
P2860
P304
P356
10.1128/AAC.47.2.594-600.2003
P407
P577
2003-02-01T00:00:00Z